OM Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of -67.5% compared to Outset Medical, Inc.'s net margin of -13.47%. Outset Medical, Inc.'s return on equity of -65.77% beat Accuray, Inc.'s return on equity of -60.6%.

Outset Medical, Inc. has a consensus price target of $10.50, signalling upside risk potential of 188.46%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 331.7%. Given that Accuray, Inc. has higher upside potential than Outset Medical, Inc., analysts believe Accuray, Inc. is more attractive than Outset Medical, Inc..

Outset Medical, Inc. has a beta of 2.079, which suggesting that the stock is 107.879% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.

Outset Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Outset Medical, Inc. quarterly revenues are $28.9M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Outset Medical, Inc.'s net income of -$19.5M is lower than Accuray, Inc.'s net income of -$13.8M. Notably, Outset Medical, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical, Inc. is 0.46x versus 0.15x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -67.5% compared to Outset Medical, Inc.'s net margin of 12.68%. Outset Medical, Inc.'s return on equity of -65.77% beat Boston Scientific Corp.'s return on equity of 12.55%.

Outset Medical, Inc. has a consensus price target of $10.50, signalling upside risk potential of 188.46%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 38.28%. Given that Outset Medical, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Outset Medical, Inc. is more attractive than Boston Scientific Corp..

Outset Medical, Inc. has a beta of 2.079, which suggesting that the stock is 107.879% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Outset Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Outset Medical, Inc. quarterly revenues are $28.9M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Outset Medical, Inc.'s net income of -$19.5M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Outset Medical, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical, Inc. is 0.46x versus 5.64x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -67.5% compared to Outset Medical, Inc.'s net margin of -316.61%. Outset Medical, Inc.'s return on equity of -65.77% beat Plus Therapeutics, Inc.'s return on equity of --.

Outset Medical, Inc. has a consensus price target of $10.50, signalling upside risk potential of 188.46%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1595.96%. Given that Plus Therapeutics, Inc. has higher upside potential than Outset Medical, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Outset Medical, Inc..

Outset Medical, Inc. has a beta of 2.079, which suggesting that the stock is 107.879% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Outset Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Outset Medical, Inc. quarterly revenues are $28.9M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Outset Medical, Inc.'s net income of -$19.5M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Outset Medical, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical, Inc. is 0.46x versus 5.20x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical, Inc. has a net margin of -67.5% compared to Outset Medical, Inc.'s net margin of -65.97%. Outset Medical, Inc.'s return on equity of -65.77% beat AVITA Medical, Inc.'s return on equity of -1112.54%.

Outset Medical, Inc. has a consensus price target of $10.50, signalling upside risk potential of 188.46%. On the other hand AVITA Medical, Inc. has an analysts' consensus of $8.41 which suggests that it could grow by 64.58%. Given that Outset Medical, Inc. has higher upside potential than AVITA Medical, Inc., analysts believe Outset Medical, Inc. is more attractive than AVITA Medical, Inc..

Outset Medical, Inc. has a beta of 2.079, which suggesting that the stock is 107.879% more volatile than S&P 500. In comparison AVITA Medical, Inc. has a beta of 1.784, suggesting its more volatile than the S&P 500 by 78.388%.

Outset Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical, Inc. pays -- of its earnings as a dividend. AVITA Medical, Inc. pays out -- of its earnings as a dividend.

Outset Medical, Inc. quarterly revenues are $28.9M, which are larger than AVITA Medical, Inc. quarterly revenues of $17.6M. Outset Medical, Inc.'s net income of -$19.5M is lower than AVITA Medical, Inc.'s net income of -$11.6M. Notably, Outset Medical, Inc.'s price-to-earnings ratio is -- while AVITA Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical, Inc. is 0.46x versus 1.99x for AVITA Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.